210 related articles for article (PubMed ID: 9474243)
1. Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin.
Calamai P; Carotti S; Guerri A; Mazzei T; Messori L; Mini E; Orioli P; Speroni GP
Anticancer Drug Des; 1998 Jan; 13(1):67-80. PubMed ID: 9474243
[TBL] [Abstract][Full Text] [Related]
2. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity.
Ronconi L; Giovagnini L; Marzano C; Bettìo F; Graziani R; Pilloni G; Fregona D
Inorg Chem; 2005 Mar; 44(6):1867-81. PubMed ID: 15762713
[TBL] [Abstract][Full Text] [Related]
3. Gold(III) complexes as a new family of cytotoxic and antitumor agents.
Marcon G; Messori L; Orioli P
Expert Rev Anticancer Ther; 2002 Jun; 2(3):337-46. PubMed ID: 12113057
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity of some gold(III) complexes.
Cossu F; Matovic Z; Radanovic D; Ponticelli G
Farmaco; 1994 Apr; 49(4):301-2. PubMed ID: 8049012
[TBL] [Abstract][Full Text] [Related]
5. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.
Farrell N; Kelland LR; Roberts JD; Van Beusichem M
Cancer Res; 1992 Sep; 52(18):5065-72. PubMed ID: 1516063
[TBL] [Abstract][Full Text] [Related]
6. Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes.
Buckley RG; Elsome AM; Fricker SP; Henderson GR; Theobald BR; Parish RV; Howe BP; Kelland LR
J Med Chem; 1996 Dec; 39(26):5208-14. PubMed ID: 8978849
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, characterization, and in vitro antitumor properties of tris(hydroxymethyl)phosphine copper(I) complexes containing the new bis(1,2,4-triazol-1-yl)acetate ligand.
Marzano C; Pellei M; Colavito D; Alidori S; Lobbia GG; Gandin V; Tisato F; Santini C
J Med Chem; 2006 Dec; 49(25):7317-24. PubMed ID: 17149861
[TBL] [Abstract][Full Text] [Related]
8. Overcoming cisplatin resistance using gold(III) mimics: anticancer activity of novel gold(III) polypyridyl complexes.
Palanichamy K; Sreejayan N; Ontko AC
J Inorg Biochem; 2012 Jan; 106(1):32-42. PubMed ID: 22112837
[TBL] [Abstract][Full Text] [Related]
9. The synthesis, chemical and biological properties of dichlorido(azpy)gold(III) chloride (azpy=2-(phenylazo)pyridine) and the gold-induced conversion of the azpy ligand to the chloride of the novel tricyclic pyrido[2,1-c][1,2,4]benzotriazin-11-ium cation.
Garza-Ortiz A; den Dulk H; Brouwer J; Kooijman H; Spek AL; Reedijk J
J Inorg Biochem; 2007 Nov; 101(11-12):1922-30. PubMed ID: 17637477
[TBL] [Abstract][Full Text] [Related]
10. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
11. Interactions of selected gold(III) complexes with calf thymus DNA.
Messori L; Orioli P; Tempi C; Marcon G
Biochem Biophys Res Commun; 2001 Feb; 281(2):352-60. PubMed ID: 11181054
[TBL] [Abstract][Full Text] [Related]
12. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
13. Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties.
Marcon G; Carotti S; Coronnello M; Messori L; Mini E; Orioli P; Mazzei T; Cinellu MA; Minghetti G
J Med Chem; 2002 Apr; 45(8):1672-7. PubMed ID: 11931621
[TBL] [Abstract][Full Text] [Related]
14. Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure.
Sun RW; Li CK; Ma DL; Yan JJ; Lok CN; Leung CH; Zhu N; Che CM
Chemistry; 2010 Mar; 16(10):3097-113. PubMed ID: 20162647
[TBL] [Abstract][Full Text] [Related]
15. Studies of the mechanism of action of platinum(II) complexes with potent cytotoxicity in human cancer cells.
Krause-Heuer AM; Grünert R; Kühne S; Buczkowska M; Wheate NJ; Le Pevelen DD; Boag LR; Fisher DM; Kasparkova J; Malina J; Bednarski PJ; Brabec V; Aldrich-Wright JR
J Med Chem; 2009 Sep; 52(17):5474-84. PubMed ID: 19658404
[TBL] [Abstract][Full Text] [Related]
16. DNA cleavage and antitumour activity of platinum(II) and copper(II) compounds derived from 4-methyl-2-N-(2-pyridylmethyl)aminophenol: spectroscopic, electrochemical and biological investigation.
Roy S; Maheswari PU; Lutz M; Spek AL; den Dulk H; Barends S; van Wezel GP; Hartl F; Reedijk J
Dalton Trans; 2009 Dec; (48):10846-60. PubMed ID: 20023915
[TBL] [Abstract][Full Text] [Related]
17. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
18. Studies of interaction of trichloro{eta2-cis-N,N-dimethyl-1-[6-(N',N'-dimethyl-ammoniummethyl)-cyclohex-3-ene-1-yl]-methylammonium}platinum(II) chloride with DNA: Effects on secondary and tertiary structures of DNA. Cytotoxic assays on human ovarian cancer cell lines, resistant and non-resistant to cisplatin.
Gay M; Montaña AM; Moreno V; Prieto MJ; Pérez JM; Alonso C
Bioorg Med Chem; 2006 Mar; 14(5):1565-72. PubMed ID: 16256352
[TBL] [Abstract][Full Text] [Related]
19. In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride.
Berners-Price SJ; Mirabelli CK; Johnson RK; Mattern MR; McCabe FL; Faucette LF; Sung CM; Mong SM; Sadler PJ; Crooke ST
Cancer Res; 1986 Nov; 46(11):5486-93. PubMed ID: 3756897
[TBL] [Abstract][Full Text] [Related]
20. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
